Pershing Square Activist Presentation Deck
A Special Meeting is Warranted Given Allergan's Record of
Poor Corporate Governance
To date, Allergan's board has responded to Valeant's highly
compelling and certain offer by refusing to engage with Valeant,
refusing to meet with Pershing Square without management present,
and by attacking Valeant's business model and management with
claims unsupported by factual evidence
Members of the board of directors of a Delaware corporation faced
with a takeover bid are required to inform themselves of all material
information about a transaction and then act with care in evaluating it.
By failing to authorize the board's advisors to meet with Valeant to
address any of the board's stated concerns about Valeant, the board
and its advisors have failed to do any reasonable investigation of the
Valeant transaction, depriving shareholders of the opportunity to
consider this offerView entire presentation